MetaCap

Nkarta Inc. (NKTX)

NASDAQ: NKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.14+0.015 (+1.34%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NKTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$81.29M
EPS (TTM)
-$1.73
52-week range
1.11 – 3.72
Day range
1.11 – 1.22
Volume / Avg
1.60M / 1.02M
Beta
—

52-week range

$1.11$3.72

NKTX stock today

Shares of Nkarta (NKTX) finished higher on Nov 20 at $1.14, a gain of 1.34% or $0.015 per share, versus the S&P 500's 3.70% decline. Shares are 69.5% below their 52-week high of $3.72, set on Jul 9, 2026 and 2.7% above the 52-week low of $1.11, near the bottom of the past year's range. NKTX is down 38.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.9%.

Nkarta has posted a net loss over the last twelve months (EPS of -$1.73), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Nkarta

Company profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Paul J. Hastings
Headquarters
South San Francisco, CA
Employees
108
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Nkarta generated $0 in revenue, up 0.0% from fiscal 2024. Nkarta reported a net loss of $104.1 million, compared with a loss of $108.8 million a year earlier. Diluted earnings per share came in at -$1.41.

Nkarta annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0———
Growth—————
Net income$-104.08M$-108.79M$-117.50M$-113.84M$-86.08M
EPS (diluted)$-1.41$-1.60$-2.40$-2.61$-2.62

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$10.50+825.11%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.45 vs $-0.40
Surprise
-12.50%

NKTX news

All NKTX news

Nkarta peers

Health Care sector
NKTX peer companies
CompanyPrice% ChgMarket capCompare
TLSATiziana Life Sciences Ltd.0.6206-8.14%$79.45Mvs NKTX
HURATuHURA Biosciences Inc.1.25-8.09%$82.20Mvs NKTX
OGIOrganigram Global Inc.0.583-7.40%$82.27Mvs NKTX
ANIXAnixa Biosciences Inc.2.44-6.15%$84.82Mvs NKTX
UPBUpstream Bio Inc.1.59-20.50%$87.15Mvs NKTX
EQEquillium Inc.1.06-5.36%$87.26Mvs NKTX
RTSNRetension Pharmaceuticals Inc.10.51-19.22%$87.57Mvs NKTX
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs NKTX

Indexes, lists and sector

Nkarta stock FAQ

What is Nkarta's stock price today?

NKTX last traded at $1.14 as of Nov 20, 4:00 PM EST, up 1.34% on the day. Prices are delayed at least 15 minutes.

Who is Nkarta's CEO?

Mr. Paul J. Hastings is the chief executive officer of Nkarta Inc., which has about 108 employees.

What is the NKTX 52-week high?

The 52-week high for NKTX is $3.72 and the 52-week low is $1.11. The stock is currently 69.5% below its high.

Compare NKTX